InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
The current price of INMD is $15.04 USD — it has increased by +0.33% in the past 24 hours. Watch Inmode stock price performance more closely on the chart.
What is Inmode stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Inmode stocks are traded under the ticker INMD.
Is Inmode stock price growing?▼
INMD stock has fallen by -1.05% compared to the previous week, the month change is a -2.08% fall, over the last year Inmode has showed a +5.99% increase.
What is Inmode market cap?▼
Today Inmode has the market capitalization of 865.46M
When is the next Inmode earnings date?▼
Inmode is going to release the next earnings report on October 28, 2026.
What were Inmode earnings last quarter?▼
INMD earnings for the last quarter are 0.35 USD per share, whereas the estimation was 0.35 USD resulting in a +1.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inmode revenue for the last year?▼
Inmode revenue for the last year amounts to 370.5M USD.
What is Inmode net income for the last year?▼
INMD net income for the last year is 93.83M USD.
How many employees does Inmode have?▼
As of August 20, 2026, the company has 660 employees.
In which sector is Inmode located?▼
Inmode operates in the Health & Wellness sector.
When did Inmode complete a stock split?▼
The last stock split for Inmode was on October 01, 2021 with a ratio of 2:1.